Nano-Encapsulation of Arsenic Trioxide Enhances Efficacy against Murine Lymphoma Model while Minimizing Its Impact on Ovarian Reserve In Vitro and In Vivo

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Ahn, Richard W ^a,b   Barrett, Susan L ^a,b   Raja, Meera R ^a   Jozefik, Jennifer K ^a,b   Spaho, Lidia ^a,b   Chen, Haimei ^a,b   Bally, Marcel B ^c,e   Mazar, Andrew P ^a,b   Avram, Michael J ^b   Winter, Jane N ^b   Gordon, Leo I ^b   Shea, Lonnie D ^a,d   O'Halloran, Thomas V ^a,b   Woodruff, Teresa K ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Northwestern University   (United States)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA; LYMPHOMA CELL LINE; MANTLE CELL LYMPHOMA; MASS SPECTROMETRY; MOUSE; NANOENCAPSULATION; NONHUMAN; OVARIAN RESERVE; OVARY FOLLICLE; OVARY FOLLICLE DEVELOPMENT; STEADY STATE; TOXICITY TESTING; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINE, TUMOR; FEMALE; FERTILITY; HUMANS; LYMPHOMA; MICE; NANOCAPSULES; OVARIAN FOLLICLE; OVARY; OXIDES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875181818     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058491     Document Type: Article

References (40)

1. Richards JS, Pangas SA, (2010) The ovary: basic biology and clinical implications. J Clin Invest 120: 963-972.
2. Woodruff TK, (2010) The Oncofertility Consortium-addressing fertility in young people with cancer. Nat Rev Clin Oncol 7: 466-475.
3. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, et al. (2004) Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 22: 4174-4183.
4. Jeruss JS, Woodruff TK, (2009) Preservation of fertility in patients with cancer. N Engl J Med 360: 902-911.
5. Levine J, Canada A, Stern CJ, (2010) Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 28: 4831-4841.
6. Agarwal SK, Chang RJ, (2007) Fertility management for women with cancer. Cancer Treat Res 138: 15-27.
7. Gracia CR, Ginsberg JP, (2007) Fertility risk in pediatric and adolescent cancers. Cancer Treat Res 138: 57-72.
8. Oktay K, Sonmezer M, (2008) Chemotherapy and amenorrhea: risks and treatment options. Curr Opin Obstet Gynecol 20: 408-415.
9. Vernaeve V, Bodri D, Colodron M, Vidal R, Durban M, et al. (2007) Endometrial receptivity after oocyte donation in recipients with a history of chemotherapy and/or radiotherapy. Hum Reprod 22: 2863-2867.
10. Douer D, Tallman MS, (2005) Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J Clin Oncol 23: 2396-2410.
11. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, et al. (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354-3360.
12. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339: 1341-1348.
13. Baljevic M, Park JH, Stein E, Douer D, Altman JK, et al. (2011) Curing all patients with acute promyelocytic leukemia: are we there yet? Hematol Oncol Clin North Am 25: 1215-1233.
14. Tallman MS, Altman JK, (2009) How I treat acute promyelocytic leukemia. Blood 114: 5126-5135.
15. Kchour G, Tarhini M, Kooshyar M-M, El Hajj H, Wattel E, et al. (2009) Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 113: 6528-6532.
16. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S, (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62: 3893-3903.
17. Dolniak B, Katsoulidis E, Carayol N, Altman JK, Redig AJ, et al. (2008) Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2. J Biol Chem 283: 12034-12042.
18. Bael TE, Peterson BL, Gollob JA, (2008) Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma Res 18: 147-151.
19. Kindler HL, Aklilu M, Nattam S, Vokes EE, (2008) Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol 31: 553-556.
20. Bhalla S, Gordon LI, David K, Prachand S, Singh AT, et al. (2010) Glutathione depletion enhances arsenic trioxide-induced apoptosis in lymphoma cells through mitochondrial-independent mechanisms. Br J Haematol 150: 365-369.
21. Chen H, Ahn R, Van den Bossche J, Thompson DH, O'Halloran TV, (2009) Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 8: 1955-1963.
22. Chen H, MacDonald RC, Li S, Krett NL, Rosen ST, et al. (2006) Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc 128: 13348-13349.
23. Ahn RW, Chen F, Chen H, Stern ST, Clogston JD, et al. (2010) A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res 16: 3607-3617.
24. Golub MS, Macintosh MS, Baumrind N, (1998) Developmental and reproductive toxicity of inorganic arsenic: animal studies and human concerns. J Toxicol Environ Health B Crit Rev 1: 199-241.
25. He W, Greenwell RJ, Brooks DM, Calderon-Garciduenas L, Beall HD, et al. (2007) Arsenic exposure in pregnant mice disrupts placental vasculogenesis and causes spontaneous abortion. Toxicol Sci 99: 244-253.
26. Holson JF, Stump DG, Clevidence KJ, Knapp JF, Farr CH, (2000) Evaluation of the prenatal developmental toxicity of orally administered arsenic trioxide in rats. Food Chem Toxicol 38: 459-466.
27. Navarro PA, Liu L, Keefe DL, (2004) In vivo effects of arsenite on meiosis, preimplantation development, and apoptosis in the mouse. Biol Reprod 70: 980-985.
28. Maziasz T, Kadambi VJ, Silverman L, Fedyk E, Alden CL, (2010) Predictive toxicology approaches for small molecule oncology drugs. Toxicol Pathol 38: 148-164.
29. Barrett SL, Shea LD, Woodruff TK, (2010) Noninvasive index of cryorecovery and growth potential for human follicles in vitro. Biol Reprod 82: 1180-1189.
30. Kreeger PK, Deck JW, Woodruff TK, Shea LD, (2006) The in vitro regulation of ovarian follicle development using alginate-extracellular matrix gels. Biomaterials 27: 714-723.
31. Shikanov A, Xu M, Woodruff TK, Shea LD, (2009) Interpenetrating fibrin-alginate matrices for in vitro ovarian follicle development. Biomaterials 30: 5476-5485.
32. Xu M, Fazleabas AT, Shikanov A, Jackson E, Barrett SL, et al. (2011) In vitro oocyte maturation and preantral follicle culture from the luteal-phase baboon ovary produce mature oocytes. Biol Reprod 84: 689-697.
33. Diehl V, Kirchner HH, Schaadt M, Fonatsch C, Stein H, et al. (1981) Hodgkin's disease: establishment and characterization of four in vitro cell lies. J Cancer Res Clin Oncol 101: 111-124.
34. Nilsson K, Giovanella BC, Stehlin JS, Klein G, (1977) Tumorigenicity of human hematopoietic cell lines in athymic nude mice. Int J Cancer 19: 337-344.
35. Tucker CA, Kapanen AI, Chikh G, Hoffman BG, Kyle AH, et al. (2008) Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Mol Cancer Ther 7: 749-758.
36. Walters KA, Allan CM, Handelsman DJ, (2008) Androgen actions and the ovary. Biol Reprod 78: 380-389.
37. Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, et al. (2003) Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 19: 575-589.
38. Desai N, Trieu V, Yao Z, Louie L, Ci S, et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12: 1317-1324.
39. Mayhew EG, Lasic D, Babbar S, Martin FJ, (1992) Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer 51: 302-309.
40. Lu WL, Qi XR, Zhang Q, Li RY, Wang GL, et al. (2004) A pegylated liposomal platform: pharmacokinetics, pharmacodynamics, and toxicity in mice using doxorubicin as a model drug. J Pharmacol Sci 95: 381-389.